Understanding how specific gene dysfunction affects bladder cancer
Official title: Defining the role of histone H3K4 mono-methyltransferase dysfunction in urothelial carcinoma
Funded at Sloan-Kettering Inst Can Research · NIH-10894874 · Data updated 2026-11-12
This study is looking at how certain gene changes might affect the development of bladder cancer, and it aims to find out more about these changes using special mouse models, which could help improve diagnosis and treatment for people with this type of cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | September 1, 2022 |
| Project end | August 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $572,189 |
| NIH project number | 5R01CA265026-03 |
| Project ID | NIH-10894874 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with urothelial carcinoma, particularly those with nonmuscle invasive or muscle invasive forms of the disease.
✕Less likely to help
Patients with other types of cancer or those without a diagnosis of urothelial carcinoma may not benefit from this research.
What this research studies
This research investigates the role of histone H3K4 mono-methyltransferase dysfunction in urothelial carcinoma, a type of bladder cancer. It focuses on understanding how mutations in certain genes contribute to the development and progression of this cancer. By using genetically engineered mouse models, the study aims to uncover the mechanisms behind these mutations and their impact on cancer behavior. The findings could lead to better diagnostic and therapeutic strategies for patients with bladder cancer.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options and outcomes for patients with bladder cancer.
How similar studies have gone: Previous research has shown promising results in understanding the genetic factors involved in bladder cancer, indicating that this approach has potential for success.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: Chen, Yu — Sloan-Kettering Inst Can Research
- Study coordinator: Chen, Yu
Related research
Other NIH-funded projects on the same topics.
-
Understanding bladder cancer biology to find new biomarkers and therapies
A study at Tuskegee University will look at the molecules inside high-grade bladder cancer to discover new markers and potential treatment targets.
-
Improved 3D guidance for kidney-sparing endoscopic UTUC treatment
A Vanderbilt team is testing a new 3D-guided approach to precisely locate and treat upper tract urothelial cancer during kidney-sparing endoscopic procedures.
-
Immune cells in bladder cancer: predicting who benefits from stronger pre-surgery therapy
This grant aims to find immune clues in muscle-invasive bladder cancer to identify which patients will best respond to intensified pre-surgery treatment.
-
Synergistic immune boost for bladder cancer with EphrinB2 blocker and PD-1 therapy
A phase II trial tests whether a new EphrinB2 blocker (sEphB4-HSA) plus pembrolizumab can help patients with muscle-invasive bladder cancer who have EphrinB2 and low Nectin4 to fight their cancer.
-
HER2 PET scans to find HER2 differences and predict response to HER2-targeted therapy in bladder cancer
This project uses a PET scan that lights up HER2 to help show which people with metastatic bladder (urothelial) cancer might benefit from HER2-targeted antibody-drug conjugates.
-
Treating bladder cancer with ARID1A gene changes
This project will develop new treatment approaches for people with bladder cancer whose tumors have changes in the ARID1A gene.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.